{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","groups":[{"description":"PHASE I: Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nPHASE II: Patients receive flavopiridol\\* as in phase I at the MTD determined in phase I.","id":"OG000","title":"Dose Level 1 (Flavopiridol 30 mg/m2 + 30 mg/m2)"},{"description":"PHASE I: Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nPHASE II: Patients receive flavopiridol\\* as in phase I at the MTD determined in phase I.","id":"OG001","title":"Dose Level 2 (Flavopiridol 30 mg/m2 + 50 mg/m2)"},{"description":"PHASE I: Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nPHASE II: Patients receive flavopiridol\\* as in phase I at the MTD determined in phase I.","id":"OG002","title":"Dose Level 3 (Flavopiridol 50 mg/m2 + 50 mg/m2)"}],"populationDescription":"Data not available due to studies were not conducted by collaborating laboratory Investigator","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Induced Response in Patients Independent of p53 Mutational Status","type":"SECONDARY"}